Efficacy of Xuebijing for coagulopathy in patients with sepsis

ABSTRACT

To provide evidence of the clinical efficacy of Xuebijing [XBJ] on blood coagulation in patients with sepsis. We conducted this meta-analysis in The People's Hospital of Liaoning Province, Shenyang, China between December 2013 and May 2014. We searched a number of databases for relevant randomized controlled trials [RCTs] published before December 2013 using the keywords [Xuebijing], [coagulation] and [sepsis]. Statistical analysis was performed with Review Manager 5.2 from the Cochrane Collaboration. Fourteen RCTs involving 867 patients were included. Compared with placebo, XBJ injection significantly improved platelets [mean differences [MD] = 42.14, 95% confidence interval [CI] 22.42 - 61.86, p<0.00001], shortened the activated partial thromboplastin time [MD = -4.81, 95% CI -7.86 - [-1.76], p=0.002], shortened the prothrombin time [MD = -2.33, 95% CI -4.15 - [-0.51], p=0.01], and shortened the thrombin time [MD = -2.05, 95% CI -3.52 - [-0.58], p=0.006]. However, no significant difference was found between the XBJ injection and the placebo group for fibrinogen [MD = 0.21, 95% CI -0.38 - 0.81, p=0.48]. Xuebijing injection may improve coagulopathy in patients with sepsis. High-quality and large sample clinical trials are needed for confirmation